State and territory governments, in conjunction with the Therapeutic Goods Administration (TGA), will determine which patient groups will receive access to medicinal cannabis products and what medicinal cannabis products can be manufactured.

A series of reviews of the evidence around the potential use of medicinal cannabis products in the following conditions is being undertaken, some of which are complete and available on the TGA website:

Find out more in the patient access section of this website or see the Access to medicinal cannabis products web page on the TGA website.